PlasmaTech Biopharmaceuticals, Inc. (NASDAQ:PTBI), formerly known as Access Pharmaceuticals, Inc., was renamed PlasmaTech in October 2014. It has 7 full-time employees and is headquartered in Dallas, Texas. It is a cancer company A biopharmaceutical company engaged in protein biotherapy research and tumor treatment drug development.
PlasmaTech Biopharmaceuticals (PTBI) company introduction:
PTBI’s currently marketed products include:
- MuGard-treatment of oral mucositis;
- ProctiGard-treatment of radiation proctitis (a common side effect of radiation therapy in the pelvic area);
- CobOral-mediating oral administration technology (using the natural vitamin B12 transport system in the human intestine);
- CobaCyte-a targeted delivery technology that can target tumor cells during cancer treatment.
PlasmaTech Biopharmaceuticals (PTBI) investment reference:
PTBI was about the same as ADRO , VLTC , GENE (also told similar stories, the stock price rose from 0.5 US dollars to 11 US dollars within a month, an increase of 2200%), etc., without any surprises, 2015-05-05 market news, Soros Has bought 5.17% of PTBI’s shares. The news pushed the stock up by more than 170% and closed up by 108.7%. It was the star stock of the day. This is the charm of small biotech stocks with low market capitalization.
PTBI official website: http://www.plasmatechbio.com/
PTBI Chinese introduction: https://www.thisyear.com/ptbi.html
